Growth hormone/insulin-like growth factor-I axis in aging: A summary of a National Institutes of Aging-Sponsored Symposium

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 12, 1997, Pages 3919-3922

  Rosen, Clifford J ^a   Conover, Cheryl ^b  

^a ST JOSEPH HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

AGING; CELL DEATH; CONFERENCE PAPER; GROWTH HORMONE RELEASE; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; SENESCENCE;

EID: 0030781729     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.12.3919     Document Type: Conference Paper

References (39)

1. Martha PM, Goorman KM, Blizzard RM, Rogol AD, Veldhuis JD. 1992 Endogenous growth hormone secretion and clearance rates in normal boys as determined by deconvolution analysis: relationship to age, pubertal status and body mass. J Clin Endocrinol Metab. 74:336-344.
2. Veldhuis JD, Liem AY, South S, et al. 1995 Differential impact of age, sex steroid hormones,and obesity on basal vs. pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 80:3209-3222.
3. Iranmanesh A Lizarralde G, Veldhuis JD. 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of GH secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 73:1081-1088.
4. Vahl N, Jorgensen JOL, Skjaerback C, Veldhuis JD, Orskov H, Christiansen J. Abdominal adiposity rather than age and sex predicts the mass and patterned regularity of GH secretion in mid-life healthy adults. Am J Physiol. In press.
5. Veldhuis JD, Iranmanesh A, Ho KK, Lizarralde G, Waters MJ, Johnson ML. 1991 Dual defects in pulsatile GH secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 72:51-59.
6. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. 1996 Older males secrete LH and testosterone more irregularly and jointly more asynchronously than younger males: dual novel facets. Proc Natl Acad Sci USA. 00:14100-14105.
7. Van den Berg G, Veldhuis JD, Frolich M, Roefsema F. 1996 An amplitude specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab. 81:2460-2466.
8. Chapman IM, Bach MA, Cauter EV, et al. 1996 Oral administration of a growth hormone secretagogue (MK-0677) to older adults enhances pulsatile GH release and restores young adult IGF-I concentrations. J Clin Endocrinol Metab. 81:4249-4257.
9. Fornito MC, Calogero AE, Mongioi A, et al. 1990 Intra-, and inter-individual variability in GH responses to GHRH. J Neuroendocrinol. 2:87-90.
10. Plotkin D, Ng J, Farmer M, et al. 1996 Use of MK-677 an oral GH secretagogue in frail elderly subjects. Growth Hormone Research Society International Meeting. November 1996 (Abstract).
11. Landin-Wilhelmens K, Wilhelmsen L, Lappas G. 1994 Serum IGF-I in a random population sample of men, and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, PTH and osteocalcin. Clin Endocrinol (Oxf). 41:351-357.
12. Clemmons DR, Underwood LE 1991 Nutritional regulation of IGF-I, and IGF binding proteins. Annu Rev Nutr. 11:393-412.
13. Ninh NX, Thissen JP, Maiter D, Adam E, Mulumba N, Ketelslegers JM. 1995 Reduced liver IGF-I gene expression in young zinc deprived rats is associated with a decrease in liver GH receptors and serum GH binding protein. J Endocrinol. 144:449-454.
14. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC. 1996 Wasting in the AIDS syndrome is associated with multiple defects in the serum IGF system. Clin Endocrinol (Oxf). 44:501-514.
15. Frost RA, Nachman SA, Lang CH, Gelato MC. 1996 Proteolysis of IGFBP-3 in human HIV positive children who fail to thrive. J Clin Endocrinol Metab. 81:2957-2962.
16. Mohan S, Farley J, Baylink DJ. 1995 Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Prog Growth Factor Res. 6:465-473.
17. Rudman D, Feller AG, Nagraj HS, et al. 1990 Effects of human GH in men over 60 years of age. N Engl J Med. 323:1-8.
18. Papadakis MA, Grady D, Black D, et al. 1996 GH replacement in healthy elder men improves body composition but not functional ability. Ann Intern Med. 124:708-716.
19. Yarasheshki KE, Zachwieja JJ, Campbell JA, Bier DM. 1995 Effects of GH and resistance exercise on muscle growth and strength in older men. Am J Physiol. 268:E268-E276.
20. Taaffe DR, Pruitt L, Reim J, et al. 1994 Effect of recombinant hGH on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 79:1361-1366.
21. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. 1994 Effect of recombinant human GH on metabolic indices,body composition and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 79:470-479.
22. Conover C. 1996 The Role of insulin-like growth factors and growth factor binding proteins in bone cell biology. In: Bilezikian J, Raisz LG, Rodan G, eds. Principles of bone biology. San Diego, CA: Academic Press; 607-619.
23. Rooyackers OE, Adey CD, Ades PA, Nair KS. 1996 Effect of age on in vivo rates of mitochondrial protein synthesis inhuman skeletal muscle. Proc Natl Acad Sci USA. 93:15364-15369.
24. Brodsky IG, Balagopal P, Nair KS. 1996 Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men. J Clin Endocrinol Metab. 81:3469-3475.
25. Glowacki J. 1995 Influence of age on human marrow. Calcif Tissue Int. 56:S50-S51.
26. Goldstein S. Moerman EJ, Jose RA, Baxter RC. 1991 IGFBP-3 accumulates to high levels in culture medium of senescent and quiescent human fibroblasts. Proc Natl Acad Sci USA. 88:9680-9684.
27. Baserga R, Resnicoff M, D'Ambrosio C, Valentinis B. 1997 The role of the IGF-I receptor in apoptosis. Vitam Horm. 53:65-98.
28. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. 1993 Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type I IGF receptor. Proc Natl Acad Sci USA. 90:11217-11221.
29. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R. 1997 The IGF-IR as a physiological relevant target of p53 in apoptosis caused by IL-3 withdrawal. Mol Cell Biol. 17:1084-1092.
30. Sell C, Baserga R, Rubin R. 1995 IGF-I and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55:303-306.
31. D'Ambrosio C, Ferver A, Resnicoff M, Baserga R. 1996 A soluble IGF-I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 56:4013-4020.
32. Plymate S, Bae V, Maddison L, Quinn L, Ware J. 1997 Reexpression of the type I IGF receptor inhibits the malignant phenotype of sv40T antigen immortalized human prostate epithelial cells. Endocrinology. 138:1728-1735.
33. Parizzas M, Saltiel AR, LeRoith D. 1997 IGF-I inhibits apoptosis using the phosphatidylinositol 3′ kinase and mitogen activated protein kinase pathways. J Biol Chem. 272:154-161.
34. Le Roith D. 1996 Signaling via the IGF-I receptor: does it differ from insulin receptor signaling? Cytokine and Growth Factor Reviews. 7:153-159.
35. Parrizas M, LeRoith D. 1997 IGF-I inhibition of apoptosis is associated with increased expression of the bcl-xl gene product. Endocrinology. 00:1355-1358.
36. Buckbinder L, Talbott R, Seizinger BR, Kley N. 1994 Proc Natl Acad Sci USA. 91:10640-10644.
37. Oh Y, Muller H, Lamson G, Rosenfeld RG. 1993 IGF-independent action of IGFBP-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 268:14964-14971.
38. Nunn Se, Gibson TB, Rajah R, Cohen P. Regulation of prostate cell growth by the IGFBPs and their proteases. Endocrine. In press.
39. Conover CA. 1995 IGFBP proteolysis in bone cell models. Prog Growth Factor Res. 6:301-309.